Biotech executive John Crowley will return to his role as CEO of Amicus Therapeutics rather than run for U.S. Senate. The company announced the move in a press release this morning, saying Crowley will return to the role in August after he finishes his temporary active duty with the United States Navy Reserve. The company announced in April that...
Speculation about a Senate run for John Crowley is likely to diminish now, as he will return to his role as CEO of biotech company Amicus Therapeutics.Biotech executive John Crowley will return to his role as CEO of Amicus Therapeutics rather than run for U.S. Senate.
The company announced the move in a press release this morning, saying Crowley will return to the role in August after he finishes his temporary active duty with the United States Navy Reserve.
The company announced in April that Crowley would transition to the less time-intensive position as executive chairman to "devote more time to interests related to public policy, civic service, and philanthropic endeavors." That was supposed to last until October, with a possible three-month extension.
And Crowley's friend and advisor, Bill Spadea, acknowledged two weeks ago to the Star-Ledger that Crowley is "very seriously looking" at a run for U.S. Senate.
In a phone interview today, Spadea said Crowley would not run.
It was about thinking through the obligations to the military, his business and his family," he said. "At this point in his life, those commitments are too great for him to be able to commit the proper time and resource for a successful senate run."
State Sen. Joseph Kyrillos (R-Monmouth), a close friend and political ally of Gov. Chris Christie, set up an exploratory committee to consider a run for the same seat this month.
U.S. Sen. Robert Menendez (D-N.J.) is up for reelection next year.
Previous coverage:
• The Auditor: Someone is taking early aim at a possible U.S. Senate contender
• Ex-biotech chief John Crowley does not confirm U.S. Senate bid
• N.J. biotech chief, U.S. Senate hopeful shifts role in company to devote time to public policy